– Full Results from Phase 3 ARTEMIS Study Will Be Featured – BRISBANE, Calif. --(BUSINESS WIRE)--May 24, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will present AR101 and patient
-- 4 in 10 Teens believe they have a great or very great chance or certainty of dying from accidental exposure -- NEW ORLEANS --(BUSINESS WIRE)--May 21, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today
BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt , will present at the RBC Capital Markets Global
- Company Enters into Commercial Supply Agreement for AR101 - BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has been informed by the U.S.
Potential FDA approval of AR101 for peanut allergy expected by late January 2020 ; Company on target to be launch-ready in Q4 2019 Submission of marketing application for AR101 in Europe on track for mid-2019, following positive topline results of ARTEMIS European Phase 3 trial Initiation of AR201
BRISBANE, Calif. --(BUSINESS WIRE)--May 1, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Wednesday, May 8, 2019 , at 4:30 p.m.
BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 3, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas , M.D., President and Chief Executive Officer, will present at the Needham &
-- Company Intends to Submit European MAA in Mid-2019 -- -- Webcast and Conference Call Today at 8:30 a.m. EDT -- BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 25, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies,
-- If Approved, AR101 Will Be the First Medicine for This Life-Threatening Condition -- BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that the
BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 5, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in three upcoming investor
